...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Neurology >The role of IVIg in autoimmune neuropathies: the latest evidence
【24h】

The role of IVIg in autoimmune neuropathies: the latest evidence

机译：IVIg在自身免疫性神经病中的作用：最新证据

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Guillain-Barré syndrome (GBS), chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and multifocal motor neuropathy (MMN) are the major immune neuropathies. Although a detailed understanding of the pathogenesis of these conditions is not yet available, the multiple effects of IVIg on the immune and inflammatory process recommend it as an agent worthy of investigation in these diseases. Following recent research, IVIg is now recommended as a first-line treatment option for moderate or severe GBS to be administered within two weeks of disease onset. With regard to CIDP, a Cochrane review demonstrated significant short-term improvements in disability and impairment with IVIg. The ICE (IGIV CIDP Efficacy trial) study group undertook the largest ever trial of IVIg for CIDP, which demonstrated for the first time the long-term efficacy of IVIg. The results of this ICE trial demonstrated the efficacy of IVIg in CIDP, with a significantly higher response rate versus placebo after 24 weeks of treatment (P = 0.0002). Furthermore, long-term maintenance with IVIg also significantly reduced the rate of relapse (P < 0.011). On the basis of available data, IVIg can be recommended as a first-line treatment option for GBS and CIDP. For MMN, although the evidence for IVIg is limited, there is no evidence to recommend other treatments.
机译：格林-巴利综合征（GBS），慢性炎性脱髓鞘性多发性神经根病（CIDP）和多灶性运动神经病（MMN）是主要的免疫神经病。尽管尚无法详细了解这些疾病的发病机理，但IVIg对免疫和炎性过程的多重作用仍将其推荐为值得研究的疾病药物。根据最近的研究，现在建议将IVIg作为中，重度GBS的一线治疗方案，在疾病发作后的两周内给予。关于CIDP，Cochrane评估显示IVIg在残疾和损伤方面的短期显着改善。 ICE（IGIV CIDP功效试验）研究小组进行了有史以来规模最大的IVIg对CIDP的试验，这首次证明了IVIg的长期疗效。这项ICE试验的结果证明了IVIg在CIDP中的疗效，治疗24周后的应答率明显高于安慰剂（P = 0.0002）。此外，使用IVIg进行长期维护也显着降低了复发率（P <0.011）。根据现有数据，可以将IVIg推荐为GBS和CIDP的一线治疗方案。对于MMN，尽管IVIg的证据有限，但没有证据推荐其他治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号